| Document |
Document Title |
|
WO/2018/111663A1 |
The instant invention provides compounds which are JAK inhibitors, and as such are useful for the treatment of JAK-mediated diseases such as rheumatoid arthritis, asthma, COPD and cancer.
|
|
WO/2018/109082A1 |
The present invention relates to a process for the preparation of 1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)eth
yl)piperazin-1-yl)ethanone and salts and solvates thereof and to the use of intermediates in the synthesis of ...
|
|
WO/2018/107100A1 |
Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treati...
|
|
WO/2018/104214A1 |
A method for producing 5-(1-phenyl-1H-pyrazole-4-yl)-nicotinamide derivatives and similar compounds of formula (I) by converting an aniline into a 1-phenyl-1H-pyrazole derivative without isolating or purifying the phenylhydrazine interme...
|
|
WO/2018/104307A1 |
Substituted aromatic sulfonamides of formula (I), pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a d...
|
|
WO/2018/107056A1 |
Disclosed are chemical entities which are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Formula (I) has the structure: R1a, R1b, R2, R3, R4a, R4b and Y are as defined herein. These chemical entities are ...
|
|
WO/2018/106459A1 |
The invention provides novel chemical compounds useful for treating one or more of autoimmune diseases, cancer, cardiovascular diseases, inflammatory diseases and diabetes, or a related disease or disorder thereof, and pharmaceutical com...
|
|
WO/2018/103583A1 |
Inhibitors with anti-inflammatory agents are provided, as are methods of using the analogs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis and autoinflammatory...
|
|
WO/2010/056999A9 |
The present invention relates to novel aryloazol-2-yl-cyanoethylamino derivatives substantially enriched in an enantiomer of formula (I): wherein R3, R4, R5, R6, R7, R13a, R13b, R14a, R14b, P, Q, V, W, X, Y, Z and a are as defined in the...
|
|
WO/2018/099952A1 |
The present invention relates to 3-amino-pyrazolo[3,4-d]pyrimidin-4-ones particularly useful as cyclin dependent kinase (CDK) inhibitors, pharmaceutical compositions comprising the same and the use thereof in particular in the prophylaxi...
|
|
WO/2018/102325A1 |
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...
|
|
WO/2018/102419A1 |
The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
|
|
WO/2018/098305A1 |
Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compound...
|
|
WO/2018/097225A1 |
Provided are a preservation solution for live cells or a composition comprising live cells and a method for using the preservation solution to preserve live cells or a composition comprising live cells, the preservative solution being ea...
|
|
WO/2018/090979A1 |
The present invention provides a compound of a formula I structure, a preparation method therefor, and applications thereof in treatment of cancers. The compound in the present invention has inhibitory effects on multiple types of cancer...
|
|
WO/2018/093696A1 |
The present invention relates to a compound represented by formula I': and pharmaceutically acceptable salts thereof. The compounds of formula I are inhibitors of diacylglyceride O-acyltransferase 2 ("DGAT2") and may be useful in the tre...
|
|
WO/2018/091338A1 |
The present invention relates to a process to produce highly purified crystalline 1-(4-chlorophenyl)pyrazol-3-ol (I).
|
|
WO/2018/093107A1 |
The present invention relates to a novel compound and an organic electroluminescent element comprising the same. The compound according to the present invention is used in an organic compound layer of an organic electroluminescent elemen...
|
|
WO/2018/090975A1 |
A compound represented by a formula I structure, and a preparation method and application in the treatment of cancer thereof are disclosed. The compound has an inhibitory effect on a plurality of cancer cells, and may be biologically tra...
|
|
WO/2018/090976A1 |
Provided are a compound of a formula I structure, a preparation method therefor, and applications thereof in treatment of cancers. The compound has inhibitory effects on multiple types of cancer cells, and can be converted into an active...
|
|
WO/2018/090137A1 |
The invention features methods for inhibiting the formation, reducing the size, and slowing the growth of an osteochondroma in a subject with multiple osteochondroma (MO) by administering to the subject palovarotene (also known as R667),...
|
|
WO/2018/089402A1 |
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...
|
|
WO/2018/089546A1 |
Isoquinoline ether compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions co...
|
|
WO/2018/087126A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I), in which A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds useful ...
|
|
WO/2018/086530A1 |
Provided is a series of sulfonamide compounds as a cccDNA inhibitor. Particularly, the present invention relates to a compound represented by formula (I) as a cccDNA inhibitor or a pharmaceutically acceptable salt thereof.
|
|
WO/2018/089695A1 |
The invention relates to compounds of formula (I): or a salt or solvate thereof, wherein the variables are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are antagonists of toll-like receptors such ...
|
|
WO/2018/089374A1 |
Compositions and methods for preventing and treating a host infected with Francisella by treating the host with AR-13 alone or in combination with antibiotics are provided.
|
|
WO/2018/083281A1 |
This invention concerns a process for the manufacture of carboxylic acids or carboxylic acid derivatives and a process for the manufacture of agrochemically and pharmaceutically active compounds comprising the process for the manufacture...
|
|
WO/2018/078097A1 |
A crystalline form of (1R,2R)-2-[4-(3-Methyl-1H-pyrazol-5-yl)benzoyl]-N-(4-oxo-4,5
,6,7-tetrahydropyrazolo[1,5-α]pyrazin-3-yl)cyclohexanecarbo
xamide, pharmaceutical compositions containing it and its use in therapy.
|
|
WO/2018/078009A1 |
The present invention relates to amido-substituted cyclohexane compounds of general formula (I) : in which m, A, R4, R6, R7, R8, R9, R10 and R11 are as defined herein, to methods of preparing said compounds, to intermediate compounds use...
|
|
WO/2018/079759A1 |
The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt of the compound. The present invention relates to: a compound represented by formula (I) or a pharmaceutically acceptable s...
|
|
WO/2018/070360A1 |
Provided are a volatile organic substance detection body and a manufacturing method therefor, a volatile organic substance detection method, and a volatile organic substance detection device that have a high selectivity, a low operating ...
|
|
WO/2018/071327A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2018/065611A1 |
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(arylsulfinyl)- acetamide compounds that, inter alia, inhibit (e.g., selectively inhibi...
|
|
WO/2018/065607A1 |
The invention relates to compounds which are suitable for the treatment of a disease associated with kallikrein related peptidase 6 overexpression and to pharmaceutical compositions containing such compounds. The invention further relate...
|
|
WO/2018/064119A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2018/059420A1 |
The present invention relates to a crystal form of a Sigma-1 receptor antagonist drug, preparation method therefor and use thereof. The crystal form of E52862 hydrochloride salt provided in the present invention, named crystal form H, ca...
|
|
WO/2018/059533A1 |
Disclosed is a class of pyrazole compounds of formula (I) having a p38α inhibitory effect, and included are uses of the compounds in the field of p38α-related diseases, such as various inflammatory diseases and immunological abnormalit...
|
|
WO/2018/053587A1 |
The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
|
|
WO/2018/057973A1 |
Disclosed are compounds of Formula I (a) or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, R5, R6, R7, G1, G2 and Ring A are as described in any of the embodiments describ...
|
|
WO/2018/055550A1 |
The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further prov...
|
|
WO/2018/054807A1 |
The present invention relates to a novel process for preparing 3-fluoroalkyl-5-pyrazolecarboxylates from ketimines and oxalic acid derivatives which can be further transformed into 3-fluoroalkyl-5- pyrazolecarboxylic acids.
|
|
WO/2018/052772A1 |
The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these comp...
|
|
WO/2018/051252A2 |
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...
|
|
WO/2018/052838A1 |
Disclosed are compounds of Formula (1), including all geometric and stereoisomers, N oxides, and salts thereof, wherein R1, R2, R3, R4 and X are as defined in the disclosure. Also disclosed are compositions containing the compounds of Fo...
|
|
WO/2018/049781A1 |
The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and the medical use thereof. In particular, the present invention relates to a compound as shown in ...
|
|
WO/2018/047670A1 |
An imide compound represented by formula (I) (in the formula, R represents a fluorine atom or hydrogen atom) exhibits excellent plant disease-preventing effects.
|
|
WO/2018/048763A1 |
The present invention is directed to indazole derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment and / or prevention of disorders and conditions ameliorated by antagonizing one or more ...
|
|
WO/2018/048762A1 |
The present invention is directed to indazole derivatives of formula (I), pharmaceutical compositions containing them and their use in the treatment and / or prevention of disorders and conditions ameliorated by antagonizing one or more ...
|
|
WO/2018/044963A1 |
The present disclosure generally relates to compounds useful as immunomodulators. Provided herein are compounds, compositions comprising such compounds, and methods of their use. The disclosure further pertains to pharmaceutical composit...
|
